LONDON, March 31 /PRNewswire/ -- Chiltern International Limited (Chiltern), a global contract research organization (CRO) announced a strategic partnership with endpoint. With this investment, Chiltern becomes a minority shareholder in the company established in April 2009.
Jonathan Dole, endpoint CEO, stated, “Chiltern’s enthusiasm and investment affirms our confidence in the solutions we are bringing to the marketplace. At endpoint, we are delighting our clients with approaches that are exceeding their needs. Our experience in the IVR/IWR space, coupled with a fresh and logical approach to systems development, is giving our customers the agility they need in a constantly changing R&D environment. We are very pleased to be working closely with Chiltern to identify and act on opportunities for synergies across our two organizations.”
Company profiles
About endpoint:
endpoint is an innovative company dedicated to the development of the leading Interactive Response Technology (IVR/IWR) platforms for the life sciences industry. endpoint’s founding team members have been developing IRT systems for clinical trials since 1998 and have deployed systems to small, medium and large pharma and biotech companies for domestic and global studies with experience across a broad range of therapeutic areas and global implementations. www.endpointclinical.com
CONTACT: Natalie Chong, Marketing Director, +44 (0) 1753 512 000, Fax, +44
(0) 1753 511 116, natalie.chong@chiltern.com, or Sue Ojanen Marketing
Associate, +1-423-968-9533, Fax, +1-423-968-3567, sue.ojanen@chiltern.com,
both of Chiltern International Ltd.; or Rich Mullikin, APR, Marketing
Director of endpoint, +1-925-779-9115, rmullikin@endpointclinical.com
Web site: http://www.chiltern.com/
http://www.endpointclinical.com/
